MindMed Reveals Topline Data From Mid-Stage Depression Study Evaluating Lysergide

Mind Medicine Inc's MNMD collaborators have released topline data from a double-blind, investigator-initiated trial evaluating lysergide major depressive disorder (MDD).
The topline data demonstrated significant, rapid, durable, and beneficial effects of lysergide and its potential to mitigate symptoms of MDD.
The high-dose lysergide regimen in which patients received 100 µg on their first treatment day and 200 µg on a second treatment day (separated by four weeks) resulted in statistically and clinically significant improvements on the primary endpoint, a change in clinician-rated Inventory of Depressive Symptomatology (IDS-C) scores six weeks after the first administration as compared to control.
IDC-C scores measure behavioral manifestations and severity of depression.
Related: MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies.
The control group in this study received a lower dose regimen of 25 µg on both treatment days.
Patients in the high dose arm (n=28) demonstrated a least square mean change from baseline in IDS-C scores of -12.9 points compared to -3.6 points in the lower dose arm (n=27, p=0.02).
The statistically significant benefit measured by IDS-C was maintained up to 16 weeks after the first administration compared to the placebo (p=0.008).
Secondary endpoints were also encouraging.
The investigational drug was generally well tolerated.
The company said that improvements observed in this study reinforce preliminary findings that have shown the clinical potential of lysergide in anxiety, depression, and other brain health disorders.
Price Action: MNMD shares closed at $3.10 on Thursday.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments